- Home
- DTF vs DBVT Comparison
DTF vs DBVT Comparison
Compare DTF & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- DBVT
- Stock Information
- Founded
- DTF 1991
- DBVT 2002
- Country
- DTF United States
- DBVT France
- Employees
- DTF N/A
- DBVT N/A
- Industry
- DTF Investment Managers
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTF Finance
- DBVT Health Care
- Exchange
- DTF Nasdaq
- DBVT Nasdaq
- Market Cap
- DTF 78.7M
- DBVT 250.5M
- IPO Year
- DTF N/A
- DBVT N/A
- Fundamental
- Price
- DTF $11.20
- DBVT $10.30
- Analyst Decision
- DTF
- DBVT Buy
- Analyst Count
- DTF 0
- DBVT 4
- Target Price
- DTF N/A
- DBVT $14.81
- AVG Volume (30 Days)
- DTF 21.1K
- DBVT 25.0K
- Earning Date
- DTF 01-01-0001
- DBVT 07-29-2025
- Dividend Yield
- DTF 3.64%
- DBVT N/A
- EPS Growth
- DTF N/A
- DBVT N/A
- EPS
- DTF 0.44
- DBVT N/A
- Revenue
- DTF N/A
- DBVT $3,497,000.00
- Revenue This Year
- DTF N/A
- DBVT $1,700.53
- Revenue Next Year
- DTF N/A
- DBVT $535.67
- P/E Ratio
- DTF $24.34
- DBVT N/A
- Revenue Growth
- DTF N/A
- DBVT N/A
- 52 Week Low
- DTF $10.29
- DBVT $2.21
- 52 Week High
- DTF $11.19
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- DTF 48.36
- DBVT 56.17
- Support Level
- DTF $11.20
- DBVT $10.11
- Resistance Level
- DTF $11.28
- DBVT $11.84
- Average True Range (ATR)
- DTF 0.04
- DBVT 0.67
- MACD
- DTF -0.00
- DBVT 0.05
- Stochastic Oscillator
- DTF 33.33
- DBVT 60.06
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.